BBL454
BBL454 (Compound 43) is a Cholecystokinin 2B (CCK2B) receptor agonist. BBL454 induces hyperactivity and improves memory in rat models while it has weak activity on the peripheral CCK2 receptor and no anxiogenic activity. BBL454 increases gastric acid output in anesthetised rat models. BBL454 can be used for diabetes research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C40H54N6O8
- Masse moléculaire:746.89
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
[1]|
CCKBR |
Chemical Information
-
Masse moléculaire 746.89
-
Formule C40H54N6O8
-
SMILES
CCCCCCC(CC(N[C@@H](CC1=CNC2=C1C=CC=C2)C(N(C)[C@@H](CCCC)C(N[C@@H](CC(O)=O)C(N[C@@H](CC3=CC=CC=C3)C(N)=O)=O)=O)=O)=O)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Pureté et documentation
Références
[1]. Bellier B, et al. New CCK2 agonists confirming the heterogeneity of CCK2 receptors: characterisation of BBL454. Naunyn Schmiedebergs Arch Pharmacol. 2004 Nov;370(5):404-13. [Content Brief]
[2]. Kalindjian SB, et al. Strategies for the design of non-peptide CCK2 receptor agonist and antagonist ligand. Curr Top Med Chem. 2007;7(12):1195-204. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)